[go: up one dir, main page]

HK1089394A1 - Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof - Google Patents

Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof

Info

Publication number
HK1089394A1
HK1089394A1 HK06111340.8A HK06111340A HK1089394A1 HK 1089394 A1 HK1089394 A1 HK 1089394A1 HK 06111340 A HK06111340 A HK 06111340A HK 1089394 A1 HK1089394 A1 HK 1089394A1
Authority
HK
Hong Kong
Prior art keywords
aplindore
derivatives
pharmaceutical compositions
sustained release
release pharmaceutical
Prior art date
Application number
HK06111340.8A
Other languages
English (en)
Inventor
Eric Joel Benjamin
Wendy Ann Dulin
Yanning Lin
Kai Zhuang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1089394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HK1089394A1 publication Critical patent/HK1089394A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
HK06111340.8A 2003-10-29 2006-10-17 Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof HK1089394A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51531503P 2003-10-29 2003-10-29
PCT/US2004/036013 WO2005044262A1 (en) 2003-10-29 2004-10-28 Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof

Publications (1)

Publication Number Publication Date
HK1089394A1 true HK1089394A1 (en) 2006-12-01

Family

ID=34572826

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06111340.8A HK1089394A1 (en) 2003-10-29 2006-10-17 Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof

Country Status (22)

Country Link
US (5) US20050095292A1 (xx)
EP (1) EP1675583B1 (xx)
JP (1) JP5547865B2 (xx)
KR (1) KR101409724B1 (xx)
CN (2) CN1874767A (xx)
AR (1) AR046222A1 (xx)
AU (1) AU2004286855B2 (xx)
BR (1) BRPI0415953B8 (xx)
CA (1) CA2543045C (xx)
ES (1) ES2405404T3 (xx)
GT (1) GT200400218A (xx)
HK (1) HK1089394A1 (xx)
IL (1) IL174958A (xx)
MX (1) MXPA06004752A (xx)
NO (1) NO20062004L (xx)
PA (1) PA8616201A1 (xx)
PE (1) PE20050484A1 (xx)
RU (1) RU2376988C2 (xx)
SG (1) SG147450A1 (xx)
TW (1) TW200517106A (xx)
WO (1) WO2005044262A1 (xx)
ZA (1) ZA200603409B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101409724B1 (ko) 2003-10-29 2014-06-19 와이어쓰 엘엘씨 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물
US8858993B2 (en) * 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
MX2008002512A (es) * 2005-08-26 2008-04-03 Bpsi Holdings Inc Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
CN102264363A (zh) * 2008-12-22 2011-11-30 诺瓦提斯公司 S1p受体激动剂的给药方案
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
EP2744496A4 (en) 2011-08-16 2015-04-08 Baker Idi Heart And Diabetes Inst Holdings Ltd FORMULATIONS WITH TAXED RELEASE
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc (n,n-二乙基胺甲醯基)甲基(2e)丁-2-烯-1,4-二酸甲酯之晶形、合成方法及用途
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CA2971071A1 (en) 2014-12-22 2016-06-30 Cardiora Pty Ltd Use of milrinone and derivatives thereof in the treatment of heart failure with preserved ejection fraction (hfpef)
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
EP3737676B1 (en) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
IL295341B2 (en) * 2018-09-28 2025-01-01 Karuna Therapeutics Inc Compositions and methods for treating diseases improved by activating muscarinic receptors
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
CN115710224A (zh) * 2020-06-28 2023-02-24 海创药业股份有限公司 一种喹啉类化合物晶型及其制备方法
CN116549406B (zh) * 2023-05-23 2023-12-19 北京丰科睿泰医药科技有限公司 一种盐酸曲唑酮缓释片剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
AU639536B2 (en) 1990-03-15 1993-07-29 Pharmacia & Upjohn Company Therapeutically useful heterocyclic indole compounds
JP2600978B2 (ja) * 1990-05-25 1997-04-16 日産自動車株式会社 サスペンションのアッパリンク支持部構造
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5168387A (en) * 1990-12-11 1992-12-01 Central Glass Company, Limited Variable light transmittance device
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5166367A (en) 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
US5189171A (en) 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
DK0605033T3 (da) 1992-12-21 2000-02-07 Duphar Int Res Enzymatisk fremgangsmåde til stereoselektiv fremstilling af en heterobicyklisk alkoholenantiomer
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US6126970A (en) * 1995-12-01 2000-10-03 Janssen Pharmaceutica N.V. Cisapride sustained release
JPH09315969A (ja) * 1996-05-24 1997-12-09 Taiyo Yakuhin Kogyo Kk イブジラスト含有徐放性医薬品組成物及びその製造方法
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
DE60042215D1 (de) * 1999-07-13 2009-06-25 Alpha Res Group Llc Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
ES2236017T3 (es) * 1999-12-03 2005-07-16 Polichem S.A. Procedimientos para la prepaaraciones farmaceuticas de liberacion sostenida de alcaloides del ergot que tienen biodfisponibilidad mejorada y composiciones de los mismos.
AU784211B2 (en) 1999-12-10 2006-02-23 Wyeth Combinations of (S)-2(benzylamino-methyl)-2,3,8,9,- tetrahydro-7H-1,4-dioxino(2,3)-E indol-8-one and neuroleptics
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
KR101409724B1 (ko) 2003-10-29 2014-06-19 와이어쓰 엘엘씨 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물
TW200811182A (en) 2006-05-25 2008-03-01 Wyeth Corp Oxindoledioxans, synthesis thereof, and intermediates thereto

Also Published As

Publication number Publication date
US11179369B2 (en) 2021-11-23
PA8616201A1 (es) 2005-05-24
AU2004286855B2 (en) 2011-04-21
CA2543045A1 (en) 2005-05-19
CA2543045C (en) 2013-12-17
SG147450A1 (en) 2008-11-28
CN102335116A (zh) 2012-02-01
AU2004286855A1 (en) 2005-05-19
WO2005044262A1 (en) 2005-05-19
KR101409724B1 (ko) 2014-06-19
AR046222A1 (es) 2005-11-30
US20180344695A1 (en) 2018-12-06
US10292966B2 (en) 2019-05-21
NO20062004L (no) 2006-07-07
RU2376988C2 (ru) 2009-12-27
KR20060110281A (ko) 2006-10-24
US10463648B2 (en) 2019-11-05
CN1874767A (zh) 2006-12-06
GT200400218A (es) 2005-06-06
ES2405404T3 (es) 2013-05-31
PE20050484A1 (es) 2005-10-13
JP5547865B2 (ja) 2014-07-16
BRPI0415953A (pt) 2007-01-02
US20230061743A1 (en) 2023-03-02
JP2007509970A (ja) 2007-04-19
TW200517106A (en) 2005-06-01
EP1675583B1 (en) 2013-02-27
IL174958A0 (en) 2008-04-13
BRPI0415953B8 (pt) 2021-05-25
ZA200603409B (en) 2010-10-27
US20200138781A1 (en) 2020-05-07
US20050095292A1 (en) 2005-05-05
EP1675583A1 (en) 2006-07-05
RU2006118321A (ru) 2007-12-10
BRPI0415953B1 (pt) 2018-12-26
MXPA06004752A (es) 2006-07-05
US20180193311A1 (en) 2018-07-12
IL174958A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
IL174958A0 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL173726A (en) Pharmaceutical compositions containing n-n-dihaloamino acids and their uses
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
HK1080717A1 (en) Pharmaceutical compositions with improved dissolution
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
IL197889A (en) Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same
IL177260A0 (en) Indazole derivatives and pharmaceutical compositions containing them
TWI319318B (en) Modified release pharmaceutical formulation
IL177496A0 (en) Amido-substituted hydroxy -6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
AU2003260803A8 (en) Sustained release pharmaceutical composition
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
IL168477A (en) Isoindoline derivatives and pharmaceutical compositions comprising them
IL176077A0 (en) 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
IL181730A0 (en) Benzodiazinone derivatives and pharmaceutical compositions containing the same
IL177498A0 (en) Difluoroethoxy -substituted hydroxy-6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211025